Form 8-K Summary
Registrant: Tivic Health Systems, Inc. (the request metadata identifies Valion Bio, Inc., which does not match the registrant named in the filing)
Reporting date: October 26, 2022. This is an Item 7.01 Regulation FD disclosure and does not report a financial period or operating results.
Business Context and Event
The company announced participation in the ThinkEquity Conference. Its Chief Executive Officer was scheduled to present at 4:00 p.m. Eastern Time on October 26, 2022. The related investor presentation was filed as Exhibit 99.1 and posted in the company’s investor-relations section of its website.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating metrics.
- The filing does not provide a clear financial outlook or quantitative guidance.
Material Changes Versus Prior Period
The filing does not disclose changes versus a prior comparable period. It is limited to notice of an investor conference presentation and related disclosures.
Guidance, Risks, and Unusual Items
- The filing contains forward-looking statements and cautions that actual results may differ materially because of known and unknown risks and uncertainties.
- It refers investors to the risks described in the filing and the company’s other SEC filings but does not identify new specific contingencies or unusual financial items.
- The Item 7.01 information and Exhibit 99.1 are furnished, not filed, for purposes of Section 18 of the Exchange Act, and generally are not incorporated by reference into other SEC filings unless expressly stated.
- The company identified itself as an emerging growth company.
Investor Verification Points
- Verify the registrant identity: the filing names Tivic Health Systems, Inc., while the request metadata names Valion Bio, Inc.
- Review Exhibit 99.1 and the company’s investor-relations website for any presentation statements, projections, business updates, or metrics not included in the filing text.
- Consult the company’s latest periodic reports for actual financial performance, cash resources, debt, liquidity, and risk factors.
- Confirm the treatment of the presentation as furnished Regulation FD material rather than filed information.